First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path," said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. "We will continue to focus on and invest in our most promising assets to bring the best value to patients."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
INGELHEIM, Germany -- Businesswire -- Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD®, a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD®, which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Boehringer Ingelheim
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자 ‘인·식바꿈’ 프로모션 실시 - 뉴스와이어
- 포트리아, 임상연구의 다양성과 포용성 개선을 위해 종합 솔루션 출시 - 뉴스와이어
- 용산구시설관리공단, 2024년 국가재난관리 유공 ‘국무총리표창’ 수상 - 뉴스와이어
- 에너지 볼트-스키드모어, 오윙스 앤 메릴, 에너지 저장을 건물 설계에 통합하는 글로벌 중력 에
- 한국환경보전원, ESG 경영 실천 위해 공공기관 협업 생태계 교란 식물 제거 활동 추진 - 뉴스와이
- 삼성전자 ‘비스포크 스팀’ 신제품 출시… 로봇청소기 라인업 확대 - 뉴스와이어
- 서틱, 온체인 혁신의 미래 형성하기 위한 ‘CertiK Ventures’ 출시 - 뉴스와이어
- UAE, 산업 오프테이크에 62억6000만달러 추가 투자 약정 확보 - 뉴스와이어
- Energy Vault and Skidmore, Owings & Merrill (SOM) Announce Exclusive Global Gravity Energy Storage Partnership to Integrate Ener
- 위프로, 시스코 및 AT&T와 협력해 리테일 미디어 제품 확대 - 뉴스와이어